

## RESEARCH LETTER

## The utility of exhaled nitric oxide in patients with suspected asthma

## ABSTRACT

The value of FE<sub>NO</sub> measurements in patients with symptoms suggestive of asthma is unclear. We performed an observational study to assess the ability of FE<sub>NO</sub> to diagnose asthma and to predict response to inhaled corticosteroids (ICS). Our findings suggest FE<sub>NO</sub> is not useful for asthma diagnosis but is accurate at predicting ICS response.

## INTRODUCTION

Data suggest that up to 40% of patients diagnosed and treated for asthma with inhaled corticosteroids (ICS) have no evidence that this treatment is needed.<sup>1</sup> Overdiagnosis of asthma is common because symptoms of the condition are non-specific<sup>2</sup> and there are no readily available tests to confidently exclude asthma.

Proposed National Institute for Health and Care Excellence (NICE) guidelines consider measurement of FE<sub>NO</sub> levels in the diagnostic algorithm,<sup>3</sup> although a recent meta-analysis concluded that the sensitivity and specificity of FE<sub>NO</sub> was insufficient for accurate diagnosis.<sup>4</sup> An alternative approach for the use of FE<sub>NO</sub> in patients with symptoms suggestive of asthma is to identify individuals who are likely to have TH2 high inflammation and therefore likely to respond to ICS.<sup>5</sup>

We aimed to establish if FE<sub>NO</sub> measurements can (1) accurately diagnose asthma in patients presenting to primary care and (2) reliably distinguish which patients will benefit from ICS treatment.

## METHODS

Adult patients with respiratory symptoms suggestive of asthma who were thought to require ICS treatment by their general practitioner (GP) were prospectively identified (see online supplementary data).

After consenting to the study (REC12/EM/0241), participants attended a baseline visit at which FE<sub>NO</sub> (NIOX MINO; Aerocrine, Tolna, Sweden), spirometry, methacholine challenge, sputum induction for sputum cell count, asthma control questionnaire (ACQ) and asthma control test (ACT) were measured and those willing returned the following day for reversibility testing with 400 µg

salbutamol inhaled via a spacer. Participants then started their GP-prescribed ICS, which was predominantly beclomethasone dipropionate (200 µg twice daily) via a metered dose inhaler, and returned at 4 and 12 weeks for repeat FE<sub>NO</sub>, spirometry, methacholine challenge, ACQ and ACT.

Diagnosis of asthma was defined as one or both:

- ▶ Reversibility of  $\geq 12\%$  and  $\geq 200$  mL in FEV<sub>1</sub>
- ▶ Provocative concentration of methacholine (PC<sub>20</sub>) of  $\leq 8$  mg/mL

Response to ICS was predefined as a combination of two of any of the following objective criteria or one objective criterion and one subjective criterion from the following predetermined criteria:

Objective:

- ▶ Increase in FEV<sub>1</sub> from baseline of  $\geq 12\%$
- ▶ Increase in PC<sub>20</sub>  $\geq$  one doubling dose<sup>6</sup>
- ▶ Decrease in FE<sub>NO</sub> of  $\geq 20\%$  for baseline values  $> 50$  ppb or decrease of  $\geq 10$  ppb for baseline values  $\leq 50$  ppb<sup>7</sup>

Subjective:

- ▶ Decrease in ACQ of  $\geq 0.5$
- ▶ Increase in ACT of  $\geq 3$  points

Data were entered into Stata (Statacorp, Texas, USA) and receiver operator characteristics (ROC) analysis was carried out in Stata and GraphPad Prism.

## RESULTS

Seventy-seven participants were included in the study, of whom 74 completed the investigations (see online supplementary data for consort diagram). Demographic details are shown in table 1. A diagnosis of asthma was made in 28 out of 74 subjects (38%). Of these, 10 were diagnosed by reversibility criteria alone and 12 were diagnosed by PC<sub>20</sub> alone, with 6 being positive on both investigations. The ROC curve to assess the utility of baseline FE<sub>NO</sub> level as a diagnostic test for asthma had an area under the curve (AUC) of 0.62 (p=0.09) (figure 1).


A response to ICS was seen in 27 out of 67 subjects (40%) after 4 weeks and 28 out of 60 subjects (47%) after 12 weeks. Of the 28 subjects with asthma, 16 (57%) had a response to ICS after

**Table 1** Demographics and clinical characteristics of subjects with and without asthma

	Subjects with asthma Frequency (%) (except*)	Subjects without asthma Frequency (%) (except*)
Total no. included for analysis	28	46
Median age (range)	29 (18–70)*	22 (18–73)*
Sex: male	11 (39)	23 (50)
Ethnic group		
Asian or Asian British	1 (3.6)	5 (10.9)
Black or Black British	4 (14.3)	0 (0)
Mixed ethnicity	1 (3.6)	0 (0)
White or White British	22 (78.6)	41 (89.1)
Smoking history		
Current	5 (17.9)	5 (10.9)
Ex-smokers	4 (14.3)	9 (19.6)
Non-smokers	19 (67.9)	32 (69.6)
Positive family history of asthma	13 (46.4)	21 (45.7)
History/symptoms of GO reflux	5 (17.9)	9 (19.6)
History/symptoms of eczema	4 (14.3)	6 (13.0)
History/symptoms of rhinitis	9 (32.1)	8 (17.4)
History/symptoms of hay fever	12 (42.9)	20 (43.5)
History of NSAID allergy	1 (3.6)	1 (2.2)
Positive skin prick for $\geq 1$ aeroallergen	17 (60.7)	26 (56.5)
	Mean (SD)	Mean (SD)
FEV <sub>1</sub> % predicted	86.7 (14.0)	96.9 (15.6)
FEV <sub>1</sub> :FVC ratio (%)	76 (10)	82.1 (8.4)
Reversibility (%)	12.6 (11.7)	3.6 (6.3)
Blood eosinophil count ( $\times 10^9/L$ )†	0.35 (0.4)	0.2 (0.1)
Baseline ACQ score	1.96 (0.81)	1.42 (0.82)
Baseline ACT score	15.8 (4.4)	17.2 (4.2)

†Data presented are median and IQR as variable not normally distributed.

ACQ, asthma control questionnaire; ACT, asthma control test; GO, gastro-oesophageal; NSAID, non-steroidal anti-inflammatory drug.



**Figure 1** (A) Receiver operator characteristic (ROC) curve analysis showing the sensitivity (%) and 100% specificity of FE<sub>NO</sub> levels for asthma diagnosis. (B) ROC curve analysis showing the sensitivity (%) and the 100% specificity of FE<sub>NO</sub> levels for predicting inhaled corticosteroids (ICS) response after 4 weeks of ICS treatment. (C) ROC curve analysis showing the sensitivity (%) and the 100% specificity of FE<sub>NO</sub> levels for predicting ICS response after 12 weeks of ICS treatment.

4 weeks, with 12 of them having sustained this response after 12 weeks. Of the non-asthmatic subjects, 11 also demonstrated a response to ICS after 4 weeks. The ROC curve for baseline FE<sub>NO</sub> level as a predictor of ICS response after 4 weeks had an AUC of 0.89 ( $p < 0.0001$ ) (figure 1). The optimal FE<sub>NO</sub> cut-off point for predicting non-response to ICS was  $< 27$  ppb (negative predictive value 93%) and for predicting response was  $> 33$  ppb (positive predictive value 92%). FEV<sub>1</sub>, PC<sub>20</sub> and blood eosinophil count did not perform as well as predictors of ICS response with AUCs between 0.32 and 0.67 (see online supplementary data).

The ability of FE<sub>NO</sub> level to predict steroid response after 12 weeks was consistent with response at 4 weeks (ROC AUC = 0.86  $p < 0.0001$ ) (figure 1).

## DISCUSSION

Our results suggest that FE<sub>NO</sub> measurement in people presenting to primary care with symptoms suggestive of asthma is more useful at predicting response to ICS than diagnosing asthma. Although our cohort was relatively small we feel our results demonstrate that using FE<sub>NO</sub> to diagnose asthma needs further investigation before being recommended in guidelines.

The poor sensitivity and specificity of FE<sub>NO</sub> in diagnosing asthma may be due to

the heterogeneity of the condition with different inflammatory subtypes expressing high or low levels of TH2 inflammation.<sup>5</sup> Hence the true utility of this test may be in detecting the presence of underlying TH2 inflammation to guide appropriate treatment with ICS, as also suggested previously by Smith *et al.*<sup>8</sup> The finding that only 57% of subjects with confirmed asthma responded to ICS further highlights the limitations of this diagnostic label.

Our study was subject to several limitations including the lack of a formal measure of ICS adherence and the definition of asthma and ICS response. Defining asthma is notoriously problematic owing to the lack of a confirmatory gold standard; defining response to ICS is also difficult. Our chosen response criteria are likely to be 'over-sensitive' in detecting a response, but are therefore less likely to miss potential responders. We included a fall in FE<sub>NO</sub> which is not used routinely but was frequently the only objective change in patients with a subjective improvement in cough and has the advantage of being easily performed in primary care. Also, it has previously been established that a reduction in TH2 inflammation is associated with a reduced risk of exacerbations,<sup>5,9</sup> bringing some validity to this approach.

We propose that FE<sub>NO</sub> measurement in patients with symptoms suggestive of airways disease could be used to identify patients in whom ICS response is highly unlikely. This could avoid unnecessary ICS treatment and encourage further investigation of the cause of the symptoms and, therefore, more effective treatment.

**M J Martin, E Wilson, W Gerrard-Tarpey, G Meakin, G Hearson, T M McKeever, D E Shaw, T W Harrison**

Nottingham Respiratory Research Unit, University of Nottingham, Nottingham City Hospital, Nottingham, UK

**Correspondence to** Dr Matthew J Martin, Nottingham Respiratory Research Unit, University of Nottingham, Room B35, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK; matthew.martin@nottingham.ac.uk

**Twitter** Follow Glenn Hearson at @NottinghamRRU

**Contributors** TWH had full access to all the data in the study, is the guarantor of the content of the manuscript, including the data and analysis, and takes responsibility for the integrity of the data and the accuracy of the data analysis, including any adverse effects. TWH, TMM and EW were co-applicants on the NIHR research for patient benefit grant. MJM, EW and WG-T contributed substantially to data collection. Sputum samples were processed by GM. MJM, EW, GH, TMM, DES and TWH contributed substantially to the study design, data analysis and interpretation and the writing of the manuscript.

**Funding** This paper summarises independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit Programme (Grant Reference Number PB-PG-1010-23145).

**Disclaimer** The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

**Competing interests** None declared.

**Ethics approval** National Research Ethics Committee East Midlands—Derby 1 (Ref 12/EM/0241).

**Provenance and peer review** Not commissioned; externally peer reviewed.

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2015-208014>).

**To cite** Martin MJ, Wilson E, Gerrard-Tarpey W, *et al.* *Thorax* Published Online First: [please include Day Month Year] doi:10.1136/thoraxjnl-2015-208014

Received 4 November 2015

Revised 27 January 2016

Accepted 28 January 2016

*Thorax* 2016;0:1–3.

doi:10.1136/thoraxjnl-2015-208014

## REFERENCES

- Lucas AE, Smeenk FW, Smeele IJ, *et al.* Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. *Fam Pract* 2008;25:86–91.
- Lim SY, Jo YJ, Chun EM. The correlation between the bronchial hyperresponsiveness to methacholine and asthma like symptoms by GINA questionnaires for the diagnosis of asthma. *BMC Pulm Med* 2014;14:161.
- National Institute for Health and Care Excellence (NICE). *Asthma—diagnosis and monitoring*. London,

- UK, 2015. <https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0640>
- 4 Li Z, Qin W, Li L, *et al*. Diagnostic accuracy of exhaled nitric oxide in asthma: a meta-analysis of 4,691 participants. *Int J Clin Exp Med* 2015;8:8516–24.
  - 5 Pavord ID, Shaw DE, Gibson PG, *et al*. Inflammometry to assess airway diseases. *Lancet* 2008;372:1017–19.
  - 6 Reddel HK, Taylor DR, Bateman ED, *et al*. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* 2009;180:59–99.
  - 7 American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005;171:912–30.
  - 8 Smith AD, Cowan JO, Brassett KP, *et al*. Exhaled nitric oxide: a predictor of steroid response. *Am J Respir Crit Care Med* 2005;172:453–9.
  - 9 Powell H, Murphy VE, Taylor DR, *et al*. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. *Lancet* 2011;378: 983–90.